Longeveron Inc. 8-K

What Happened
Longeveron Inc. (LGVN) filed an 8-K reporting that Interim CEO Than Powell resigned as Interim Chief Executive Officer on February 9, 2026, but will remain with the company in his prior business development role. The Board appointed Stephen H. Willard as permanent Chief Executive Officer effective February 11, 2026. Mr. Willard, age 65, brings more than 30 years of pharmaceutical and biotech leadership, including recent CEO roles at ICaPath, NRx Pharmaceuticals and Cellphire, and service on the National Science Board.

Key Details

• CEO appointment effective: February 11, 2026. Interim CEO Than Powell stepped down from the interim role on February 9, 2026 but stays at the company in business development.
• Compensation: Willard’s base salary is $500,000/year, with an initial Deferral Period reducing his pay to $250,000/year (50% deferral) starting on or about February 9, 2026; company may pay salary in cash or equity at its discretion.
• Equity awards: initial grant includes 200,000 shares of Class A common stock, 200,000 restricted stock units (RSUs), and a stock option for 200,000 shares; awards vest quarterly over four years.
• Cost-cutting actions: effective on or about February 16, 2026, the company implemented a temporary 50% reduction in compensation for the CEO and Executive Chairman/CSO, furloughed certain employees, reduced board fees, restricted travel and other cuts. The company intends, subject to finances and board approval, to grant each executive 50,000 RSUs vesting around June 1, 2026, and may (but is not guaranteed to) repay reduced salary amounts later if funds allow.

Why It Matters
This filing signals a leadership transition to an experienced biotech executive and simultaneous near-term cost controls. The temporary salary deferrals and other expense cuts indicate the company is managing a constrained cash runway and may need additional financing; restoration of pay or repayment of deferred amounts is contingent on securing funds and is not guaranteed. New equity awards to the incoming CEO are material for shareholders because they provide compensation alignment but may be dilutive over time. Investors should note the company's explicit focus on cash conservation and the conditional nature of any future compensation restoration.